Phase 1 Dose Escalating and Expansion Study of ONO-4578 Given as Monotherapy and Combinations of ONO-4578 and ONO-4538 in Subjects With Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary) ; ONO 4578 (Primary)
- Indications Gastric cancer; Solid tumours
- Focus Adverse reactions; Biomarker
- Sponsors Ono Pharmaceutical
- 09 Sep 2019 Planned number of patients changed from 54 to 91.
- 09 Sep 2019 Planned End Date changed from 1 Sep 2019 to 1 Sep 2021.
- 09 Sep 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Sep 2021.